Barbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, Jim Küppers, Euy Sung Moon, Milka Marinova, Ralph Alexander Bundschuh, Glen Kristiansen, Markus Essler, Frank Roesch, Florian Christoph Gaertner
{"title":"神经内分泌肿瘤肝转移灶中成纤维细胞活化蛋白抑制剂(FAPi)阳性肿瘤分数与Ki-67的相关性","authors":"Barbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, Jim Küppers, Euy Sung Moon, Milka Marinova, Ralph Alexander Bundschuh, Glen Kristiansen, Markus Essler, Frank Roesch, Florian Christoph Gaertner","doi":"10.1055/a-1521-8604","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Gallium-68-labelled inhibitors of the fibroblast activation protein (FAPi) enable positron emission tomography/computed tomography (PET/CT) imaging of fibroblast activation. We evaluated if [<sup>68</sup>Ga]Ga-DATA5m.SA.FAPi PET/CT is related to Ki-67 as a marker of tumour aggressiveness in patients with liver metastases of NET.</p><p><strong>Methods: </strong>Thirteen patients with liver metastases of a histologically confirmed NET who underwent PET/CT with [<sup>68</sup>Ga]Ga-DATA5m.SA.FAPi, [18F]FDG and [<sup>68</sup>Ga]Ga-DOTA-TOC were retrospectively analyzed. PET-positive liver tumour volumes were segmented for calculation of volume, SUVmax and PET-positive tumour fraction (TF). PET parameters were correlated with Ki-67.</p><p><strong>Results: </strong>FDG<sub>SUVmax</sub> correlated positively (rho = 0.543, p < 0.05) and DOTATOC<sub>SUVmax</sub> correlated negatively (rho = -0.618, p < 0.05) with Ki-67, the correlation coefficients were in the moderate range. There was no significant correlation between FAPi<sub>SUVmax</sub> and Ki-67 (rho = 0.382, p > 0.05). FAPi<sub>TF</sub> correlated positively (rho = 0.770, p < 0.01) and DOTATOC<sub>TF</sub> correlated negatively (rho = -0.828, p < 0.01) with Ki-67, both significantly with high correlation coefficients. FDG<sub>TF</sub> also correlated significantly with Ki-67, with a moderate correlation coefficient (rho = 0.524, p < 0.05). The ratio FAPi<sub>VOL</sub>:DOTATOC<sub>VOL</sub> showed a significant and strong correlation with Ki-67 (rho = 0.808, p < 0.01).</p><p><strong>Conclusion: </strong>The ratio FAPi<sub>VOL</sub>:DOTATOC<sub>VOL</sub> might serve as a clinical parameter for the assessment of dedifferentiation and aggressiveness of liver metastases in patients with NET. [<sup>68</sup>Ga]Ga-DATA5m.SA.FAPi might hold potential for identification of high-risk patients. Further studies are warranted to evaluate its prognostic significance in comparison to [<sup>18</sup>F]FDG in patients with NET.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 5","pages":"344-354"},"PeriodicalIF":1.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.\",\"authors\":\"Barbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, Jim Küppers, Euy Sung Moon, Milka Marinova, Ralph Alexander Bundschuh, Glen Kristiansen, Markus Essler, Frank Roesch, Florian Christoph Gaertner\",\"doi\":\"10.1055/a-1521-8604\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Gallium-68-labelled inhibitors of the fibroblast activation protein (FAPi) enable positron emission tomography/computed tomography (PET/CT) imaging of fibroblast activation. We evaluated if [<sup>68</sup>Ga]Ga-DATA5m.SA.FAPi PET/CT is related to Ki-67 as a marker of tumour aggressiveness in patients with liver metastases of NET.</p><p><strong>Methods: </strong>Thirteen patients with liver metastases of a histologically confirmed NET who underwent PET/CT with [<sup>68</sup>Ga]Ga-DATA5m.SA.FAPi, [18F]FDG and [<sup>68</sup>Ga]Ga-DOTA-TOC were retrospectively analyzed. PET-positive liver tumour volumes were segmented for calculation of volume, SUVmax and PET-positive tumour fraction (TF). PET parameters were correlated with Ki-67.</p><p><strong>Results: </strong>FDG<sub>SUVmax</sub> correlated positively (rho = 0.543, p < 0.05) and DOTATOC<sub>SUVmax</sub> correlated negatively (rho = -0.618, p < 0.05) with Ki-67, the correlation coefficients were in the moderate range. There was no significant correlation between FAPi<sub>SUVmax</sub> and Ki-67 (rho = 0.382, p > 0.05). FAPi<sub>TF</sub> correlated positively (rho = 0.770, p < 0.01) and DOTATOC<sub>TF</sub> correlated negatively (rho = -0.828, p < 0.01) with Ki-67, both significantly with high correlation coefficients. FDG<sub>TF</sub> also correlated significantly with Ki-67, with a moderate correlation coefficient (rho = 0.524, p < 0.05). The ratio FAPi<sub>VOL</sub>:DOTATOC<sub>VOL</sub> showed a significant and strong correlation with Ki-67 (rho = 0.808, p < 0.01).</p><p><strong>Conclusion: </strong>The ratio FAPi<sub>VOL</sub>:DOTATOC<sub>VOL</sub> might serve as a clinical parameter for the assessment of dedifferentiation and aggressiveness of liver metastases in patients with NET. [<sup>68</sup>Ga]Ga-DATA5m.SA.FAPi might hold potential for identification of high-risk patients. Further studies are warranted to evaluate its prognostic significance in comparison to [<sup>18</sup>F]FDG in patients with NET.</p>\",\"PeriodicalId\":19238,\"journal\":{\"name\":\"Nuklearmedizin-nuclear Medicine\",\"volume\":\"60 5\",\"pages\":\"344-354\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuklearmedizin-nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-1521-8604\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/7/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1521-8604","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 11
摘要
目的:镓-68标记的成纤维细胞激活蛋白(FAPi)抑制剂能够实现成纤维细胞激活的正电子发射断层扫描/计算机断层扫描(PET/CT)成像。我们评估了[68Ga]Ga-DATA5m.SA。FAPi PET/CT与Ki-67作为NET肝转移患者肿瘤侵袭性的标志物相关。方法:13例经组织学证实的NET肝转移患者行PET/CT扫描[68Ga]Ga-DATA5m.SA。回顾性分析FAPi、[18F]FDG和[68Ga]Ga-DOTA-TOC。对pet阳性肝肿瘤体积进行分割，计算体积、SUVmax和pet阳性肿瘤分数(TF)。PET参数与Ki-67相关。结果:FDGSUVmax与Ki-67呈正相关(rho = 0.543, p < 0.05)， DOTATOCSUVmax与Ki-67负相关(rho = -0.618, p < 0.05)，相关系数均在中等范围内。FAPiSUVmax与Ki-67无显著相关(rho = 0.382, p > 0.05)。FAPiTF与Ki-67呈正相关(rho = 0.770, p < 0.01)， DOTATOCTF与Ki-67呈负相关(rho = -0.828, p < 0.01)，均具有极显著的高相关系数。FDGTF与Ki-67也有显著相关，相关系数为中等(rho = 0.524, p < 0.05)。FAPiVOL:DOTATOCVOL比值与Ki-67呈显著强相关(rho = 0.808, p < 0.01)。结论:FAPiVOL:DOTATOCVOL比值可作为评价NET患者肝转移去分化及侵袭性的临床指标。ga [68] Ga-DATA5m.SA。FAPi可能具有识别高危患者的潜力。需要进一步的研究来评估其与[18F]FDG在NET患者中的预后意义。
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
Aim: Gallium-68-labelled inhibitors of the fibroblast activation protein (FAPi) enable positron emission tomography/computed tomography (PET/CT) imaging of fibroblast activation. We evaluated if [68Ga]Ga-DATA5m.SA.FAPi PET/CT is related to Ki-67 as a marker of tumour aggressiveness in patients with liver metastases of NET.
Methods: Thirteen patients with liver metastases of a histologically confirmed NET who underwent PET/CT with [68Ga]Ga-DATA5m.SA.FAPi, [18F]FDG and [68Ga]Ga-DOTA-TOC were retrospectively analyzed. PET-positive liver tumour volumes were segmented for calculation of volume, SUVmax and PET-positive tumour fraction (TF). PET parameters were correlated with Ki-67.
Results: FDGSUVmax correlated positively (rho = 0.543, p < 0.05) and DOTATOCSUVmax correlated negatively (rho = -0.618, p < 0.05) with Ki-67, the correlation coefficients were in the moderate range. There was no significant correlation between FAPiSUVmax and Ki-67 (rho = 0.382, p > 0.05). FAPiTF correlated positively (rho = 0.770, p < 0.01) and DOTATOCTF correlated negatively (rho = -0.828, p < 0.01) with Ki-67, both significantly with high correlation coefficients. FDGTF also correlated significantly with Ki-67, with a moderate correlation coefficient (rho = 0.524, p < 0.05). The ratio FAPiVOL:DOTATOCVOL showed a significant and strong correlation with Ki-67 (rho = 0.808, p < 0.01).
Conclusion: The ratio FAPiVOL:DOTATOCVOL might serve as a clinical parameter for the assessment of dedifferentiation and aggressiveness of liver metastases in patients with NET. [68Ga]Ga-DATA5m.SA.FAPi might hold potential for identification of high-risk patients. Further studies are warranted to evaluate its prognostic significance in comparison to [18F]FDG in patients with NET.
期刊介绍：
Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar.
Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.
Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.
Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
